Home › News › Quality / GMP

Novartis Receives Positive CHMP Opinion for Cosentyx in Adolescent Hidradenitis Suppurativa in Europe

Novartis Receives Positive CHMP Opinion for Cosentyx in Adolescent Hidradenitis Suppurativa in Europe

Novartis announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending marketing authorisation for Cosentyx (secukinumab) for adolescents aged 12 years and older with active moderate to severe Hidradenitis Suppurativa (HS) who have shown an inadequate response to conventional systemic HS therapy.

If approved by the European Commission (EC), Cosentyx would become the only interleukin-17A (IL-17A) inhibitor approved for adolescent HS in Europe and the first innovative biologic treatment option for this patient population in nearly a decade. The recommendation is expected to address an unmet medical need, as treatment options for adolescents with the condition remain limited.

Hidradenitis suppurativa is a chronic, progressive and often painful inflammatory skin disease characterised by recurring boil-like abscesses that can rupture, resulting in open wounds and potentially irreversible scarring. The condition commonly affects intimate areas of the body, and more than 50 percent of cases begin during puberty.

Commenting on the development, Dr John Ingram, Clinical Professor at Cardiff University School of Medicine, United Kingdom, said that HS often begins during adolescence, a critical period when the disease can progress and cause irreversible scarring. He highlighted that the positive CHMP opinion represents an important step towards addressing the limited treatment options available for young patients.

The CHMP recommendation is supported by evidence indicating that weight-based dosing of Cosentyx in adolescents aged 12 years and older provides drug exposure generally comparable to that observed in adults with HS. The evidence includes efficacy and safety findings from adult HS clinical studies, pharmacokinetic modelling based on adult HS and psoriasis trials, paediatric clinical trial data from other approved Cosentyx indications, and weight-based dosing analyses.

Cosentyx has an established safety profile across several approved adult and paediatric indications. The therapy is a fully human biologic that directly inhibits interleukin-17A, a cytokine involved in the inflammatory processes associated with multiple immune-mediated diseases.

Patrick Horber, President, International, Novartis, said the positive CHMP opinion brings the company closer to expanding advanced treatment options for adolescents living with moderate to severe HS. He also highlighted Cosentyx's role in treating several immune-mediated diseases over the past decade.

The European Commission is expected to issue its final decision within approximately two months following the CHMP recommendation.

Cosentyx is currently approved for adults with several conditions, including psoriatic arthritis, moderate to severe plaque psoriasis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, hidradenitis suppurativa and polymyalgia rheumatica. Its paediatric approvals include plaque psoriasis and certain subtypes of juvenile idiopathic arthritis, including juvenile psoriatic arthritis and enthesitis-related arthritis. In the United States, it is also approved for paediatric patients aged 12 years and older with moderate to severe HS.

More news about: quality / gmp | Published by News Bureau | November - 16 - 2026

Last news about this category


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members